CRSPN.MX
SellHot AirCRISPR Therapeutics AG · Healthcare · Switzerland · $5.6B · Avg Vol: $4K/d
Hot Air: Rising on momentum alone: weak business, rich price.
20
StockRankGet insider-trade alerts
QualityQuality
24
ValueValue
26
MomentumMomentum
54
P/E (TTM)
—
peers 29.9x
ROE
-26.1%
peers 11.4%
D/E
0.4x
peers 0.4x
Dividend %
—
trailing yield
ABOUT CRISPR THERAPEUTICS AG
Read
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.
FINANCIAL SUMMARY (MXN)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.5M | 6.4B | 602.6M | 0 | 796.0% | 230.6M | 703.1M | 2.7B | 64.8% |
| EPS (MXN) | -143.95 | -33.40 | -74.73 | -111.40 | — | -81.47 | — | — | — |
| Shares | 78.5M | 80.0M | 85.7M | 95.9M | +22.1% | 96.7M | — | — | — |
| Debt | 4.2B | 4.1B | 3.9B | 3.6B | -5.4% | 13.5B | — | — | — |
| Equity | 32.3B | 32.4B | 33.3B | 33.1B | 0.8% | — | — | — | — |
| Op CF | -8.5B | -4.5B | -2.5B | -5.9B | — | -6.4B | — | — | — |
| Inv CF | -4.5B | 6.5B | -4.8B | -547.6M | — | — | — | — | — |
| Fin CF | 664.5M | 1.1B | 5.7B | 7.3B | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+19.2%
SMA 50SMA 200
Close
$56.13
RSI (14)
0.0
52W High
$80.03
From 52W High
0.7%
SCORE BREAKDOWN
Quality
24
ROIC
-25.3%26.7
ROE
-26.1%27.1
GP/Assets
-20.4%4.7
Op. Margin
-1127.6%6.5
FCF/Assets
-16.5%23.5
Piotroski
29.5
Int. Cover
—N/A
D/E Ratio
0.45x31.4
Current Ratio
17.85x94.9
Value
26
P/E (TTM)
—N/A
EV/EBITDA
-10.4x25.0
P/FCF
—N/A
P/B
2.8x47.1
P/S
406.7x3.4
Div Yield
—N/A
Momentum
54
52W High %
70%50.8
RS 6M
13%73.6
SMA 50/200
0.99x53.2
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$5.6B
P/E (Forward)
—
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CRSPN.MX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CRSPN.MX | CRISPR Therapeutics AG(you) | $5.6B | 20 | Sell |
| PHVS | Pharvaris N.V. | $2.5B | 21 | Sell |
| IDIA.SW | Idorsia Ltd | $1.7B | 22 | Sell |
| BANB.SW | Bachem Holding AG | $7.1B | 53 | Hold |
| MLTX | MoonLake Immunotherapeutics | $1.3B | 8 | Strong Sell |
| OCS | Oculis Holding AG | $678M | 6 | Strong Sell |
| SANN.SW | Santhera Pharmaceuticals Holding AG | $290M | 20 | Sell |
| ACIU | AC Immune SA | $299M | 13 | Strong Sell |
| MOLN.SW | Molecular Partners AG | $172M | 19 | Strong Sell |
| BION.SW | BB Biotech AG | $3.8B | 100 | Strong Buy |
Peer medians: ROE 11.4% · P/E 29.9x · Gross margin 62.5%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.